Your session is about to expire
← Back to Search
Olaparib for Solid Tumors
This trial will study how well olaparib works in treating patients with certain types of cancer that have spread and usually cannot be controlled with treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Solid Tumors
- Low Grade Glioma
- Brain Tumor
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2023 Phase 3 trial • 154 Patients • NCT02184195
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You are pregnant.You are expected to live for at least 16 weeks.You have had cancer, other than some specific types, within the past 5 years.You are currently breastfeeding.You cannot be taking any other experimental drugs.You have participated in another study that involves testing a new or experimental medication in the last 30 days or within five half-lives of the drug.You are allergic to olaparib or any of the ingredients in the medication.You cannot have received any chemotherapy or radiation treatment within the past three weeks before starting the study.Your tumor must be easy to reach for biopsy, and you must be willing to undergo multiple biopsies.If you have cancerous growths outside of your brain, there must be at least one that can be easily measured or examined.
- Group 1: Treatment (olaparib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What supplementary investigations have been performed utilizing Olaparib?
"Olaparib first underwent clinical trials in 2005 at Research Site, with 63 studies having been completed since. Currently, 188 active trials are being carried out across the United States of America - many of which originated from Overland Park, Kansas."
How many subjects are being included in this medical research?
"In order to complete the study, 145 eligible participants are needed. The research will take place at two University of Kansas locations: Hospital-Indian Creek Campus in Overland Park and Westwood Cancerf Kansas locations: Hospital-Indian Creek Campus in Overland Park and Westwood Cancer Center in Westwood."
Is this experiment pathbreaking in its approach?
"Olaparib has been under clinical study since 2005, with the first trial sponsored by AstraZeneca. After its Phase 1 approval in 2005 following a 98-patient sample size evaluation, there are presently 188 ongoing trials of Olaparib spread over 1468 cities and 59 countries worldwide."
In what quantity of medical establishments is this experiment being conducted?
"This clinical trial is currently being offered from 34 different sites, including Overland Park, Westwood and Nashville. To reduce the need for long-distance travel during your participation in this study, we recommend selecting a site close to you."
Are new participants being enrolled in this medical experiment?
"Affirmative. According to the clinical trials website, this medical experiment is currently recruiting participants. Initially posted on March 30th 2018 and most recently updated October 18th 2022, 145 patients are needed from 34 sites across the country."
To what extent can patients rely on Olaparib to be secure?
"The safety rating for Olaparib was 2, as the Phase 2 trial has yet to produce any evidence of efficacy. This score is based on existing data that points towards its safety."
What pathologies can be ameliorated through the utilization of Olaparib?
"Olaparib is used to treat a range of maladies, including advance directives and the cancerous growths in the ovary or peritoneum. Additionally, it can be effective against hallucinations, somatic."
Share this study with friends